Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Extragenital lichen sclerosus

Heidi Jacobe, MD
Section Editor
Jeffrey Callen, MD, FACP, FAAD
Deputy Editor
Abena O Ofori, MD


Lichen sclerosus (also known as lichen sclerosus et atrophicus) is a chronic inflammatory disorder characterized by the presence of porcelain white, atrophic plaques on the skin. Most cases of lichen sclerosus involve the female genitalia; extragenital manifestations occur in a minority of patients.

The epidemiology, clinical manifestations, and treatment of extragenital lichen sclerosus will be reviewed here. Anogenital lichen sclerosus is discussed separately. (See "Vulvar lichen sclerosus" and "Balanitis in adults".)


Extragenital manifestations are estimated to occur in approximately 15 to 20 percent of patients with lichen sclerosus [1]. Similar to genital lichen sclerosus, extragenital disease appears to be more common in women than in men. In a retrospective review, 17 out of 20 patients with histopathologic findings consistent with extragenital lichen sclerosus were female [2]. The disorder is rare in children.


The pathogenesis of lichen sclerosus is not well understood, and most information on this subject has been derived from studies in genital disease. Proposed etiologic factors for lichen sclerosus have included immune dysfunction, genetic predisposition, infectious agents, and trauma [3-12]. (See "Vulvar lichen sclerosus", section on 'Etiology'.)


Extragenital lichen sclerosus can occur in any location on the skin and infrequently appears in the oral cavity. Concomitant vulvar or penile lichen sclerosus may or may not be present. Conjunctival lesions do not occur.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Sep 06, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Powell JJ, Wojnarowska F. Lichen sclerosus. Lancet 1999; 353:1777.
  2. Carlson JA, Lamb P, Malfetano J, et al. Clinicopathologic comparison of vulvar and extragenital lichen sclerosus: histologic variants, evolving lesions, and etiology of 141 cases. Mod Pathol 1998; 11:844.
  3. Sander CS, Ali I, Dean D, et al. Oxidative stress is implicated in the pathogenesis of lichen sclerosus. Br J Dermatol 2004; 151:627.
  4. Dillon WI, Saed GM, Fivenson DP. Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America. J Am Acad Dermatol 1995; 33:617.
  5. Weide B, Walz T, Garbe C. Is morphoea caused by Borrelia burgdorferi? A review. Br J Dermatol 2000; 142:636.
  6. Cooper SM, Ali I, Baldo M, Wojnarowska F. The association of lichen sclerosus and erosive lichen planus of the vulva with autoimmune disease: a case-control study. Arch Dermatol 2008; 144:1432.
  7. Chan I, Oyama N, Neill SM, et al. Characterization of IgG autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Clin Exp Dermatol 2004; 29:499.
  8. Oyama N, Chan I, Neill SM, et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet 2003; 362:118.
  9. Oyama N, Chan I, Neill SM, et al. Development of antigen-specific ELISA for circulating autoantibodies to extracellular matrix protein 1 in lichen sclerosus. J Clin Invest 2004; 113:1550.
  10. Kowalewski C, Kozłowska A, Chan I, et al. Three-dimensional imaging reveals major changes in skin microvasculature in lipoid proteinosis and lichen sclerosus. J Dermatol Sci 2005; 38:215.
  11. Anderton RL, Abele DC. Lichen sclerosus et atrophicus in a vaccination site. Arch Dermatol 1976; 112:1787.
  12. Yates VM, King CM, Dave VK. Lichen sclerosus et atrophicus following radiation therapy. Arch Dermatol 1985; 121:1044.
  13. Neill SM, Lewis FM, Tatnall FM, et al. British Association of Dermatologists' guidelines for the management of lichen sclerosus 2010. Br J Dermatol 2010; 163:672.
  14. Libow LF, Coots NV. Lichen sclerosus following the lines of Blaschko. J Am Acad Dermatol 1998; 38:831.
  15. Choi SW, Yang JE, Park HJ, Kim CW. A case of extragenital lichen sclerosus following Blaschko's lines. J Am Acad Dermatol 2000; 43:903.
  16. Farris DR, Hardy D, Kagen MH, et al. Extragenital pigmented lichen sclerosus. J Eur Acad Dermatol Venereol 2000; 14:322.
  17. Ballester I, Bañuls J, Pérez-Crespo M, Lucas A. Extragenital bullous lichen sclerosus atrophicus. Dermatol Online J 2009; 15:6.
  18. Garrido-Ríos AA, Alvarez-Garrido H, Sanz-Muñoz C, et al. Dermoscopy of extragenital lichen sclerosus. Arch Dermatol 2009; 145:1468.
  19. Forschner A, Metzler G, Rassner G, Fierlbeck G. Morphea with features of lichen sclerosus et atrophicus at the site of a herpes zoster scar: another case of an isotopic response. Int J Dermatol 2005; 44:524.
  20. Noakes RR, Spelman L. Köbnerization in a woman with generalized lichen sclerosus. Australas J Dermatol 2004; 45:144.
  21. Attili VR, Attili SK. Lichen sclerosus of lips: a clinical and histopathologic study of 27 cases. Int J Dermatol 2010; 49:520.
  22. Azevedo RS, Romañach MJ, de Almeida OP, et al. Lichen sclerosus of the oral mucosa: clinicopathological features of six cases. Int J Oral Maxillofac Surg 2009; 38:855.
  23. Kelly SC, Helm KF, Zaenglein AL. Lichen sclerosus of the lip. Pediatr Dermatol 2006; 23:500.
  24. Jensen T, Worsaae N, Melgaard B. Oral lichen sclerosus et atrophicus: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94:702.
  25. Kim CY, Kim JG, Oh CW. Treatment of oral lichen sclerosus with 1% pimecrolimus cream. Ann Dermatol 2010; 22:326.
  26. Wakamatsu J, Yamamoto T, Uchida H, Tsuboi R. Lichen sclerosus et atrophicus of the lip: successful treatment with topical tacrolimus. J Eur Acad Dermatol Venereol 2008; 22:760.
  27. Lutz V, Francès C, Bessis D, et al. High frequency of genital lichen sclerosus in a prospective series of 76 patients with morphea: toward a better understanding of the spectrum of morphea. Arch Dermatol 2012; 148:24.
  28. Kreuter A, Wischnewski J, Terras S, et al. Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center. J Am Acad Dermatol 2012; 67:1157.
  29. Uitto J, Santa Cruz DJ, Bauer EA, Eisen AZ. Morphea and lichen sclerosus et atrophicus. Clinical and histopathologic studies in patients with combined features. J Am Acad Dermatol 1980; 3:271.
  30. Tremaine R, Adam JE, Orizaga M. Morphea coexisting with lichen sclerosus et atrophicus. Int J Dermatol 1990; 29:486.
  31. Vázquez MG, Navarra R, Martin-Urda MT, et al. Lichen Sclerosus et Atrophicus with Cutaneous Distribution Simulating Lichen Planus. Case Rep Dermatol 2010; 2:55.
  32. Corbalán-Vélez R, Pérez-Ferriols A. Lichen sclerosus et atrophicus affecting the wrists and left ankle and clinically simulating lichen planus. Cutis 2001; 67:417.
  33. Goldstein AT, Creasey A, Pfau R, et al. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol 2011; 64:e99.
  34. Ayhan A, Guven S, Guvendag Guven ES, et al. Topical testosterone versus clobetasol for vulvar lichen sclerosus. Int J Gynaecol Obstet 2007; 96:117.
  35. Lorenz B, Kaufman RH, Kutzner SK. Lichen sclerosus. Therapy with clobetasol propionate. J Reprod Med 1998; 43:790.
  36. Dalziel KL, Millard PR, Wojnarowska F. The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05%) cream. Br J Dermatol 1991; 124:461.
  37. Sauder MB, Linzon-Smith J, Beecker J. Extragenital bullous lichen sclerosus. J Am Acad Dermatol 2014; 71:981.
  38. Colbert RL, Chiang MP, Carlin CS, Fleming M. Progressive extragenital lichen sclerosus successfully treated with narrowband UV-B phototherapy. Arch Dermatol 2007; 143:19.
  39. Chen JF, Chiang CP, Chen YF. Bilateral zosteriform extragenital lichen sclerosus et atrophicus: a new clinical presentation. J Dermatol 2010; 37:480.
  40. Bergstrom KG, Mengden SJ, Kamino H, Ramsay D. Extragenital lichen sclerosus et atrophicus. Dermatol Online J 2008; 14:23.
  41. Marren P, De Berker D, Millard P, Wojnarowska F. Bullous and haemorrhagic lichen sclerosus with scalp involvement. Clin Exp Dermatol 1992; 17:354.
  42. Kreuter A, Gambichler T. Narrowband UV-B phototherapy for extragenital lichen sclerosus. Arch Dermatol 2007; 143:1213.
  43. Kreuter A, Gambichler T, Avermaete A, et al. Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study. J Am Acad Dermatol 2002; 46:251.
  44. Dalmau J, Baselga E, Roé E, Alomar A. Psoralen-UVA treatment for generalized prepubertal extragenital lichen sclerosus et atrophicus. J Am Acad Dermatol 2006; 55:S56.
  45. Valdivielso-Ramos M, Bueno C, Hernanz JM. Significant improvement in extensive lichen sclerosus with tacrolimus ointment and PUVA. Am J Clin Dermatol 2008; 9:175.
  46. Kim GW, Park HJ, Kim HS, et al. Topical tacrolimus ointment for the treatment of lichen sclerosus, comparing genital and extragenital involvement. J Dermatol 2012; 39:145.
  47. Arican O, Ciralik H, Sasmaz S. Unsuccessful treatment of extragenital lichen sclerosus with topical 1% pimecrolimus cream. J Dermatol 2004; 31:1014.
  48. Kreuter A, Gambichler T, Sauermann K, et al. Extragenital lichen sclerosus successfully treated with topical calcipotriol: evaluation by in vivo confocal laser scanning microscopy. Br J Dermatol 2002; 146:332.
  49. Greve B, Hartschuh W, Raulin C. [Extragenital lichen sclerosus et atrophicus - treatment with pulsed dye laser]. Hautarzt 1999; 50:805.
  50. Passeron T, Lacour JP, Ortonne JP. Comparative treatment of extragenital lichen sclerosus with methylaminolevulinic Acid pulsed dye laser-mediated photodynamic therapy or pulsed dye laser alone. Dermatol Surg 2009; 35:878.
  51. Kartamaa M, Reitamo S. Treatment of lichen sclerosus with carbon dioxide laser vaporization. Br J Dermatol 1997; 136:356.
  52. Kreuter A, Tigges C, Gaifullina R, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate treatment in patients with refractory generalized extragenital lichen sclerosus. Arch Dermatol 2009; 145:1303.
  53. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31:645.
  54. Nayeemuddin F, Yates VM. Lichen sclerosus et atrophicus responding to methotrexate. Clin Exp Dermatol 2008; 33:651.
  55. Wakelin SH, James MP. Extensive lichen sclerosus et atrophicus with bullae and ulceration--improvement with hydroxychloroquine. Clin Exp Dermatol 1994; 19:332.
  56. Rajlawat BP, Triantafyllou A, Field EA, Parslew R. Lichen sclerosus of the lip and buccal mucosa. Clin Exp Dermatol 2004; 29:684.
  57. Buajeeb W, Kraivaphan P, Punyasingh J, Laohapand P. Oral lichen sclerosus et atrophicus. A case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88:702.
  58. Brown AR, Dunlap CL, Bussard DA, Lask JT. Lichen sclerosus et atrophicus of the oral cavity: report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84:165.
  59. Macleod RI, Soames JV. Lichen sclerosus et atrophicus of the oral mucosa. Br J Oral Maxillofac Surg 1991; 29:64.
  60. Sergeant A, Vernall N, Mackintosh LJ, et al. Squamous cell carcinoma arising in extragenital lichen sclerosus. Clin Exp Dermatol 2009; 34:e278.
  61. Sotillo Gago I, Martínez Sahuquillo A, Matilla A, García Pérez A. [Spinocellular epithelioma following scleroatrophic autoaneous licher]. Actas Dermosifiliogr 1977; 68:219.